Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease
Received clearance of LX2006 Clinical Trial Application (CTA) in Canada for the treatment of FA cardiomyopathy; activated first clinical trial site outside of the United States
Related news for (LXEO)
- Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
- 24/7 Market News Snapshot 17 October, 2025 – Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO)
- Morning Market Brief: Quiet Rockets and Loud Leaders
- Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
- 24/7 Market News Snapshot 07 October, 2025 – Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO)
